![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FANK1 |
Gene summary for FANK1 |
![]() |
Gene information | Species | Human | Gene symbol | FANK1 | Gene ID | 92565 |
Gene name | fibronectin type III and ankyrin repeat domains 1 | |
Gene Alias | HSD13 | |
Cytomap | 10q26.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8TC84 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
92565 | FANK1 | C21 | Human | Oral cavity | OSCC | 4.67e-03 | 1.85e-01 | 0.2678 |
92565 | FANK1 | C30 | Human | Oral cavity | OSCC | 6.66e-09 | 4.27e-01 | 0.3055 |
92565 | FANK1 | C08 | Human | Oral cavity | OSCC | 4.27e-09 | 1.69e-01 | 0.1919 |
92565 | FANK1 | LN38 | Human | Oral cavity | OSCC | 8.51e-03 | 5.99e-01 | 0.168 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00510907 | Oral cavity | OSCC | regulation of DNA-binding transcription factor activity | 221/7305 | 440/18723 | 9.06e-07 | 1.23e-05 | 221 |
GO:00510917 | Oral cavity | OSCC | positive regulation of DNA-binding transcription factor activity | 134/7305 | 260/18723 | 2.52e-05 | 2.35e-04 | 134 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FANK1 | SNV | Missense_Mutation | novel | c.614C>T | p.Ala205Val | p.A205V | Q8TC84 | protein_coding | tolerated(0.34) | benign(0.239) | TCGA-KK-A8I7-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Hormone Therapy | leuprolide | SD |
FANK1 | SNV | Missense_Mutation | novel | c.211G>C | p.Val71Leu | p.V71L | Q8TC84 | protein_coding | tolerated(0.31) | benign(0.001) | TCGA-KK-A8II-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Hormone Therapy | lupron | PD |
FANK1 | SNV | Missense_Mutation | rs199770819 | c.236N>T | p.Thr79Met | p.T79M | Q8TC84 | protein_coding | deleterious(0) | benign(0.184) | TCGA-BR-8487-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |